Literature DB >> 29720396

Primary repair versus surgical and transcatheter palliation in infants with tetralogy of Fallot.

Dan M Dorobantu1,2,3, Alireza S Mahani4, Mansour T A Sharabiani5, Ragini Pandey1, Gianni D Angelini3, Andrew J Parry1, Robert M R Tulloh1,3, Robin P Martin1, Serban C Stoica1,3.   

Abstract

OBJECTIVES: Treatment of infants with tetralogy of Fallot (ToF) has evolved in the last two decades with increasing use of primary surgical repair (PrR) and transcatheter right ventricular outflow tract palliation (RVOTd), and fewer systemic-to-pulmonary shunts (SPS). We aim to report contemporary results using these treatment options in a comparative study.
METHODS: This a retrospective study using data from the UK National Congenital Heart Disease Audit. All infants (n=1662, median age 181 days) with ToF and no other complex defects undergoing repair or palliation between 2000 and 2013 were considered. Matching algorithms were used to minimise confounding due to lower age and weight in those palliated.
RESULTS: Patients underwent PrR (n=1244), SPS (n=311) or RVOTd (n=107). Mortality at 12 years was higher when repair or palliation was performed before the age of 60 days rather than after, most significantly for primary repair (18.7% vs 2.2%, P<0.001), less so for RVOTd (10.8% vs 0%, P=0.06) or SPS (12.4% vs 8.3%, P=0.2). In the matched groups of patients, RVOTd was associated with more right ventricular outflow tract (RVOT) reinterventions (HR=2.3, P=0.05 vs PrR, HR=7.2, P=0.001 vs SPS) and fewer pulmonary valve replacements (PVR) (HR=0.3 vs PrR, P=0.05) at 12 years, with lower mortality after complete repair (HR=0.2 versus PrR, P=0.09).
CONCLUSIONS: We found that RVOTd was associated with more RVOT reinterventions, fewer PVR and fewer deaths when compared with PrR in comparable, young infants, especially so in those under 60 days at the time of the first procedure. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  congenital heart disease surgery; pulmonic valve disease; tetralogy of fallot; transcatheter valve interventions

Mesh:

Year:  2018        PMID: 29720396     DOI: 10.1136/heartjnl-2018-312958

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  4 in total

1.  The Limited Benefit of Follow-Up Echocardiograms After Repair of Tetralogy of Fallot.

Authors:  Jack Xu; Caleb Guthrey; Stephen Dalby; Xinyu Tang; Joshua Daily; R Thomas Collins
Journal:  Pediatr Cardiol       Date:  2019-09-18       Impact factor: 1.655

2.  Long-term follow-up after transatrial-transpulmonary repair of tetralogy of Fallot: influence of timing on outcome.

Authors:  Eva van den Bosch; Ad J J C Bogers; Jolien W Roos-Hesselink; Arie P J van Dijk; Marie H E J van Wijngaarden; Eric Boersma; Aagje Nijveld; Linda W G Luijten; Ronald Tanke; Laurens P Koopman; Willem A Helbing
Journal:  Eur J Cardiothorac Surg       Date:  2020-04-01       Impact factor: 4.191

3.  German Registry for Cardiac Operations and Interventions in Patients with Congenital Heart Disease: Report 2021 and 9 Years' Longitudinal Observations on Fallot and Coarctation Patients.

Authors:  Sven Dittrich; Claudia Arenz; Otto Krogmann; Anja Tengler; Renate Meyer; Ulrike Bauer; Michael Hofbeck; Andreas Beckmann; Alexander Horke
Journal:  Thorac Cardiovasc Surg       Date:  2022-09-29       Impact factor: 1.756

Review 4.  Tetralogy of Fallot Will be Treated Interventionally Within Two Decades.

Authors:  Muhammed Riyas K Rahmath; Younes Boudjemline
Journal:  Pediatr Cardiol       Date:  2020-03-20       Impact factor: 1.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.